Research programme: histone deacetylase inhibitors - BioMarin

Drug Profile

Research programme: histone deacetylase inhibitors - BioMarin

Alternative Names: BMN-290; HDAC inhibitors - BioMarin

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Repligen Corporation
  • Developer BioMarin Pharmaceutical; Repligen Corporation
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Friedreich's ataxia
  • No development reported Huntington's disease
  • Discontinued Cognition disorders; Spinal muscular atrophy

Most Recent Events

  • 26 Oct 2017 Preclinical trials in Friedreich's ataxia in USA (PO)
  • 26 Oct 2017 BioMarin announces intention to submit IND for BMN 290 for Freidriech's ataxia in the second half of 2018
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top